Solventum Corp. Q3 2026 Earnings - SOLVENTUM CORP

Explicit Guidance:

• FY 2026 Organic Sales Growth: Guidance raised to the high end of 2.5%–3% range (approx. 3.0%), implying normalized growth near 4% excluding 100 bps SKU exit impact.
• FY 2026 Reported Sales: Expect ~100 bps favorable impact from foreign currency exchange.
• FY 2026 Gross Margin: Expected at ~57%, including 120 bps benefit from Q2 tariff refund offsetting full-year tariff costs.
• FY 2026 Operating Margin: Expected toward high end of 22.2%–22.7% range (up from initial 21%–21.5% + 120 bps tariff benefit). Excluding tariff refund, implies ~100 bps expansion vs. prior year (150 bps underlying expansion if removing annualized tariff comps).
• FY 2026 Non-Operating Expense: ~$300 million (unchanged).
• FY 2026 Effective Tax Rate: 19.5%–20.5% (unchanged).
• FY 2026 EPS: Raised to $7.20–$7.30 (up from $7.10–$7.20), including ~$0.35 impact from Q2 ERP advanced order reversal.
• FY 2026 Free Cash Flow: Maintained at $200–$300 million; underlying cash generation ~$1 billion excluding separation/portfolio costs. Majority expected in Q4.
• FY 2028 Long-Range Plan (LRP): Full code target of 23%–25% operating margin confirmed with increased confidence.
• RemainCo (post-HIS separation) Long-Range Plan: Aggregate market growth rate of 4%–5%; organic sales growth target of 4%–5%. Expected ~400 bps annualized net operating margin dilution initially, with accelerated margin improvement over time.

Business-Segment Outlook:

• MedSurge: Organic growth expected to remain robust; Negative Pressure Wound Therapy (NPWT) to continue ramping with "VAC Peel-in-Place" dressing; Pravena growth on single-use side; IV site management gains with Tegaderm CHG and Kuros caps; Sterilization Assurance products fully in market.
• Acera Integration: On track; business delivered best quarter on record with ~35% growth.
• Dental: New product launches (ClinPro Clear, Filtek Easy Match, composite warmer, Clarity aligner attachments) driving growth; Clarity composite veneers limited launch phase initiated, with full launch expected in H1 2027.
• Health Information Systems (HIS): Revenue cycle management (360, Compass) and AI-driven autonomous coding apps expanding; international expansion continuing.
• Portfolio Actions: Purification and filtration divestiture moving on plan; HIS separation process (spin vs. sale) advancing; SKU rationalization program ending Q1 2027, removing 100 bps headwind.

Market and Competitive Outlook:

• Growth Drivers: Five growth drivers (NPWT, IV site management, sterilization, core restoratives, revenue cycle) represent multi-billion dollar opportunity; strategy focuses on underpenetrated customers rather than displacing incumbents.
• NPWT Opportunity: VAC Peel-in-Place technology targets ~90% of the remaining market opportunity where clinical therapy is unused due to workflow friction; 61% reduction in application time and 7-day wear capability.
• Acera Synergies: Restrata + NPWT 510k clearance enables co-marketing, leveraging combined commercial orgs; no change to growth trajectory but confirms assumptions.
• Dental Market: Stable market conditions; growth driven by share gains and new product penetration rather than market expansion.

Macro / Industry Outlook:

• Tariffs: Q2 tariff refund benefit (450 bps to Q2 margins, 120 bps annualized) offsetting expected full-year tariff costs; confident in managing 2027 tariff headwinds without the refund.
• Raw Material Supply: Successfully renegotiated long-term supply agreement with 3M, eliminating a scheduled ~100 bps gross margin step-up in April 2027 and strengthening supply continuity.
• Inflation & Costs: Offsetting factors include inflation and ongoing investments, but "Transform for the Future" program savings and portfolio optimization are expected to drive margin expansion.
• Foreign Exchange: Anticipated ~100 bps favorable impact on FY 2026 reported sales growth.
• Credit Rating: Proceeds from HIS separation intended to pay down debt to maintain investment-grade rating.

Strategic Initiatives:

• Separation from 3M: >90% complete; ERP cutover finished; >90% of transition service agreements exited; remaining 9 manufacturing line moves and 9 distribution center exits expected by end of 2027. Separation costs to step-down in Q4 2026 and 2027.
• HIS Separation: Intent to separate Health Information Systems via spin or sale; proceeds to be used for debt paydown and shareholder returns.
• Transform for the Future Program: $180M spent of $500M estimated cost; $160M of targeted $500M annual savings achieved. Program expected to continue expanding margins and absorbing stranded costs/tariffs through 2027.
• Shareholder Returns: ~$50M in repurchases in Q3 (570k shares); ~$400M total YTD; majority of HIS separation proceeds expected to be returned to shareholders.
• Acera Tuck-ins: Continued focus on tuck-in acquisitions within the optimized sales channel.

Risks and Headwinds to Outlook:

• ERP Timing: Q3 included reversal of 125M in advanced orders (630 bps headwind); future quarters expected to normalize.
• SKU Rationalization: 100 bps headwind from SKU exits in FY 2026, ending in Q1 2027.
• HIS Separation Dilution: ~400 bps annualized net operating margin dilution expected post-separation, to be offset by RemainCo growth levers.
• Tariff Headwinds: 2027 will face tariff costs without the 2026 refund benefit; management confidence relies on resolved supply agreement and cost savings.
• Execution Risk: Remaining 10% of separation activities (rebranding, 9 line moves, 9 DC exits) through end of 2027; rebranding noted as "longest tail."

Management Tone on the Future:

• Confidence: High confidence in margin expansion trajectory for 2027 despite tariff headwinds, citing resolved supply agreements and "Transform for the Future" program momentum.
• Separation: Described separation as "risky work done," retiring execution risk and strengthening free cash flow.
• Strategy: Emphasis on "say-do equation" and disciplined capital allocation; RemainCo described as "more focused, more disciplined" with "compelling and enhanced growth and margin acceleration opportunity."
• Investor Day: Full details on growth levers and pipeline to be presented at Investor Day in March 2027.

Miscellaneous:

• FY 2026 ERP Mitigation: Q3 included $125M reversal of advanced orders; Q2 also included similar timing impacts which are now netted out for full-year view.
• Acera 510k: Received clearance for combined use of Restrata with VAC therapy faster than expected, enabling immediate co-marketing.
• Clarity Veneers: Early market access validated with 1,000+ smiles; full launch in H1 2027.